RNA interference in head and neck oncology (Review)

Sobecka,Agnieszka; Barczak,Wojciech; Suchorska,Wiktoria Maria

doi:10.3892/ol.2016.5079

RNA interference in head and neck oncology (Review)

Authors:
- Agnieszka Sobecka
- Wojciech Barczak
- Wiktoria Maria Suchorska
View Affiliations

Affiliations: Department of Medical Physics, Radiobiology Laboratory, Greater Poland Cancer Centre, Poznan University of Medical Sciences, 61‑866 Poznan, Poland
Published online on: September 2, 2016 https://doi.org/10.3892/ol.2016.5079
Pages: 3035-3040
Copyright: © Sobecka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer worldwide. The treatment of choice in case of head and neck cancer is surgery, followed by chemo‑ or/and radiotherapy. A potentially effective instrument to improve the outcome of numerous diseases, including viral infections, diabetes and cancer, is RNA interference (RNAi). It has been demonstrated that small interfering RNA and microRNA molecules are strongly involved in the regulation of various different pathological processes in cancer development. RNAi has become a valuable research tool allowing a better understanding of the mechanisms regulating cancer pathogenesis. Considering those advantages over other current therapeutics (including specificity and high efficacy), RNAi appears to be a potentially useful tool in cancer treatment. The present review discusses the current knowledge about the possibility of using RNAi in HNSCC therapy.

View Figures

View References

1	Suh Y, Amelio I, Urbano T Guerrero and Tavassoli M: Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI
2	Thomas SM and Grandis JR: The current state of head and neck cancer gene therapy. Hum Gene Ther. 20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
3	Maiti GP, Mondal P, Mukherjee N, Ghosh A, Ghosh S, Dey S, Chakrabarty J, Roy A, Biswas J, Roychoudhury S and Panda CK: Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One. 8:e634402013. View Article : Google Scholar : PubMed/NCBI
4	Martinez-Useros J and Garcia-Foncillas J: The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncol. 51:423–430. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ahn SH, Choi JY, Kim DW, Lee DY, Jeon EH, Jeong WJ and Paik JH: Targeting HIF1α peri-operatively increased post-surgery survival in a tongue cancer animal model. Ann Surg Oncol. 22:3041–3048. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liang J, Zhang Z, Liang L, Shen Y and Ouyang K: HIF-1α regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model. Ann Transl Med. 2:922014.PubMed/NCBI
7	Hamilton AJ and Baulcombe D: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 286:950–952. 1999. View Article : Google Scholar : PubMed/NCBI
8	Napoli C, Lemieux C and Jorgensen R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 2:279–289. 1990. View Article : Google Scholar : PubMed/NCBI
9	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
10	Collins RE and Cheng X: Structural and biochemical advances in mammalian RNAi. J Cell Biochem. 99:1251–1266. 2006. View Article : Google Scholar : PubMed/NCBI
11	Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK and Mukherjee SK: RNA interference: Biology, mechanism, and applications. Microbiol Mol Biol Rev. 67:657–685. 2003. View Article : Google Scholar : PubMed/NCBI
12	Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase III drosha initiates microRNA processing. Nature. 425:415–419. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wilson RC and Doudna JA: Molecular mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2003. View Article : Google Scholar
14	Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 15:331–341. 2005. View Article : Google Scholar : PubMed/NCBI
15	Liu Q and Paroo Z: Biochemical principles of small RNA pathways. Annu Rev Biochem. 79:295–319. 2010. View Article : Google Scholar : PubMed/NCBI
16	Ouellet DL, Perron MP, Gobeil LA, Plante P and Provost P: MicroRNAs in gene regulation: When the smallest governs it all. J Biomed Biotechnol. 2006:696162006. View Article : Google Scholar : PubMed/NCBI
17	Yeom KH, Lee Y, Han J, Suh MR and Kim VN: Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res. 34:4622–4629. 2006. View Article : Google Scholar : PubMed/NCBI
18	Khvorova A, Reynolds A and Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell. 115:209–216. 2003. View Article : Google Scholar : PubMed/NCBI
19	Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell. 115:199–208. 2003. View Article : Google Scholar : PubMed/NCBI
20	Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G and Tuschl T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 15:185–197. 2004. View Article : Google Scholar : PubMed/NCBI
21	Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W and Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20:6877–6888. 2001. View Article : Google Scholar : PubMed/NCBI
22	Eulalio A, Huntzinger E and Izaurralde E: Getting to the root of miRNA-mediated gene silencing. Cell. 132:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
23	Gregory RI, Chendrimada TP, Cooch N and Shiekhattar R: Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 123:631–640. 2005. View Article : Google Scholar : PubMed/NCBI
24	Meister G: miRNAs get an early start on translational silencing. Cell. 131:25–28. 2007. View Article : Google Scholar : PubMed/NCBI
25	Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G and Sood AK: RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer. 11:59–67. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bouard D, Alazard-Dany D and Cosset FL: Viral vectors: From virology to transgene expression. Br J Pharmacol. 157:153–165. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kantor B, Bailey RM, Wimberly K, Kalburgi SN and Gray SJ: Methods for gene transfer to the central nervous system. Adv Genet. 87:125–197. 2014.PubMed/NCBI
28	Galanis E, Vile R and Russell SJ: Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hemato. 38:177–192. 2001. View Article : Google Scholar
29	Morris KV and Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wold WS and Toth K: Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 13:421–433. 2013. View Article : Google Scholar : PubMed/NCBI
31	Hermens WT and Verhaagen J: Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol. 55:399–432. 1998. View Article : Google Scholar : PubMed/NCBI
32	Tomar RS, Matta H and Chaudhary PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene. 22:5712–5715. 2003. View Article : Google Scholar : PubMed/NCBI
33	Lentz TB, Gray SJ and Samulski RJ: Viral vectors for gene delivery to the central nervous system. Neurobiol Dis. 48:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
34	Ramamoorth M and Narvekar A: Non viral vectors in gene therapy-an overview. J Clin Diagn Res. 9:GE01–GE06. 2015.PubMed/NCBI
35	Uprichard SL: The therapeutic potential of RNA interference. FEBS Lett. 579:5996–6007. 2005. View Article : Google Scholar : PubMed/NCBI
36	Chen WH, Lecaros RL, Tseng YC, Huang L and Hsu YC: Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett. 359:65–74. 2015. View Article : Google Scholar : PubMed/NCBI
37	Sasabe E, Tatemoto Y, Li D, Yamamoto T and Osaki T: Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci. 96:394–402. 2005. View Article : Google Scholar : PubMed/NCBI
38	Sasabe E, Zhou X, Li D, Oku N, Yamamoto T and Osaki T: The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer. 120:268–277. 2007. View Article : Google Scholar : PubMed/NCBI
39	Mimeault M and Batra SK: Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 17:30–54. 2013. View Article : Google Scholar : PubMed/NCBI
40	Jing S, Wang J, Liu Q, Cheng Y, Yang C, Wang Y, Cao F, Wen B, Jiao W and Guo Y: Relationship between hypoxia inducible factor-1α and esophageal squamous cell carcinoma: A meta analysis. Zhonghua Bing Li Xue Za Zhi. 43:593–599. 2014.(In Chinese). PubMed/NCBI
41	Xie J, Jin B, Li DW, Shen B, Cong N, Zhang TZ and Dong P: ABCG2 regulated by MAPK pathways is associated with cancer progression in laryngeal squamous cell carcinoma. Am J Cancer Res. 4:698–709. 2014.PubMed/NCBI
42	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
43	Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, Zhang L and Han Z: Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer. 126:841–851. 2010.PubMed/NCBI
44	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 5:53–64. 2014.
45	Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 15:1084–1103. 2012. View Article : Google Scholar
46	Nakanishi T and Ross DD: Breast cancer resistance protein (BCRP/ABCG2): Its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 31:73–99. 2012. View Article : Google Scholar : PubMed/NCBI
47	Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
48	Steglich A, Vehlow A, Eke I and Cordes N: α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells. Cancer Lett. 357:542–548. 2015. View Article : Google Scholar : PubMed/NCBI
49	Hehlgans S, Haase M and Cordes N: Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta. 1775:163–180. 2007.PubMed/NCBI
50	Onodera Y, Nam JM and Sabe H: Intracellular trafficking of integrins in cancer cells. Pharmacol Ther. 140:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
51	Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
52	Lukacs RU, Memarzadeh S, Wu H and Witte ON: Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell. 7:682–693. 2010. View Article : Google Scholar : PubMed/NCBI
53	Li Z, Wang Y, Yuan C, Zhu Y, Qiu J, Zhang W, Qi B, Wu H, Ye J, Jiang H, et al: Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer. Lab Invest. 94:1431–1445. 2014. View Article : Google Scholar : PubMed/NCBI
54	Mazumdar A, Henderson YC, El-Naggar AK, Sen S and Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 31:625–634. 2009. View Article : Google Scholar : PubMed/NCBI
55	Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998. View Article : Google Scholar : PubMed/NCBI
56	Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D and Brinkley WR: Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. 62:4115–4122. 2002.PubMed/NCBI
57	Kovarikova V, Burkus J, Rehak P, Brzakova A, Solc P and Baran V: Aurora kinase A is essential for correct chromosome segregation in mouse zygote. Zygote. 15:326–337. 2016. View Article : Google Scholar
58	Katsha A, Belkhiri A, Goff L and El-Rifai W: Aurora kinase A in gastrointestinal cancers: Time to target. Mol Cancer. 20:1062015. View Article : Google Scholar
59	Sun JM, Yang LN, Xu H, Chang B, Wang HY and Yang G: Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI
60	Tanaka H, Nakashiro K, Iwamoto K, Tokuzen N, Fujita Y, Shirakawa R, Oka R, Goda H and Hamakawa H: Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo. Oral Oncol. 49:551–559. 2013. View Article : Google Scholar : PubMed/NCBI
61	Whitehead KA, Langer R and Anderson DG: Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov. 8:129–138. 2009. View Article : Google Scholar : PubMed/NCBI
62	U.S. National Institutes of Health, . ClinicalTrials.gov: ClinicalTrials.gov Background. Available from. https://clinicaltrials.gov/ct2/about-site/backgroundAccessed. June 29–2015
63	U.S. National Institutes of Health, . ClinicalTrials.gov: APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery. Available from. http://clinicaltrials.gov/show/NCT02166255Accessed. June 29–2015
64	U.S. National Institutes of Health, . ClinicalTrials.gov: EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery. Available from. http://clinicaltrials.gov/show/NCT01591356Accessed. June 29–2015
65	U.S. National Institutes of Health, . ClinicalTrials.gov: Safety Study of CALAA-01 to Treat Solid Tumor Cancers. Available from. http://clinicaltrials.gov/show/NCT00689065Accessed. June 29–2015.
66	U.S. National Institutes of Health, . ClinicalTrials.gov: Phase I-Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas. Available from. http://clinicaltrials.gov/show/NCT01188785Accessed. June 29–2015.
67	U.S. National Institutes of Health, . ClinicalTrials.gov: A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. Available from. http://clinicaltrials.gov/show/NCT01676259Accessed. June 29–2015